In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endologix Hopes Nellix Deal Is A Winning Hand

Executive Summary

AAA company Endologix Inc. is carving a niche for itself in the crowded endovascular aneurysm repair field with two new products. It has developed a method of delivering aortic aneurysm grafts through a percutaneous opening, but the company’s larger opportunity might lie in a piece of technology acquired three years ago – the Nellix Endovascular Aneurysm Sealing system.

You may also be interested in...



News Briefs: Illumina Genomics Incubator; Invacare Plant Closure; New Products

Illumina launches incubator for next-gen sequencing. Invacare will close a Canada manufacturing facility. New products from Tryton, Endologix and Cook. More news.

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

Virus-Hit Astellas Cuts Forecast

Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel